1.20
price up icon2.56%   0.03
after-market アフターアワーズ: 1.17 -0.03 -2.50%
loading
前日終値:
$1.17
開ける:
$1.17
24時間の取引高:
1.02M
Relative Volume:
0.68
時価総額:
$138.42M
収益:
$13.45M
当期純損益:
$-178.23M
株価収益率:
-0.7273
EPS:
-1.65
ネットキャッシュフロー:
$-132.53M
1週間 パフォーマンス:
+14.29%
1か月 パフォーマンス:
+12.15%
6か月 パフォーマンス:
+28.16%
1年 パフォーマンス:
-4.00%
1日の値動き範囲:
Value
$1.145
$1.205
1週間の範囲:
Value
$1.05
$1.205
52週間の値動き範囲:
Value
$0.6611
$1.9399

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
名前
Fate Therapeutics Inc
Name
セクター
Healthcare (1112)
Name
電話
858.875.1803
Name
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
職員
181
Name
Twitter
@fatethx
Name
次回の収益日
2025-08-08
Name
最新のSEC提出書
Name
FATE's Discussions on Twitter

Compare FATE vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
FATE
Fate Therapeutics Inc
1.20 134.96M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
465.02 117.03B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
783.65 82.35B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
833.54 51.64B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
308.48 42.58B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
346.42 38.87B 4.98B 69.60M 525.67M 0.5198

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-10-31 アップグレード H.C. Wainwright Neutral → Buy
2025-10-27 アップグレード Wedbush Neutral → Outperform
2024-11-18 アップグレード BofA Securities Underperform → Neutral
2024-06-17 アップグレード Piper Sandler Neutral → Overweight
2023-03-27 再開されました Wells Fargo Equal Weight
2023-01-24 ダウングレード H.C. Wainwright Buy → Neutral
2023-01-06 ダウングレード BMO Capital Markets Outperform → Market Perform
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2023-01-06 ダウングレード Cowen Outperform → Market Perform
2023-01-06 ダウングレード Piper Sandler Overweight → Neutral
2023-01-06 ダウングレード Stifel Buy → Hold
2023-01-06 ダウングレード Truist Buy → Hold
2023-01-06 ダウングレード Wedbush Outperform → Neutral
2023-01-03 ダウングレード Guggenheim Buy → Neutral
2022-12-22 ダウングレード Oppenheimer Outperform → Perform
2022-12-15 開始されました Goldman Sell
2022-11-04 再開されました Cantor Fitzgerald Overweight
2022-10-10 開始されました Canaccord Genuity Buy
2022-08-18 再開されました Wells Fargo Overweight
2022-07-28 開始されました Needham Hold
2022-07-11 アップグレード BMO Capital Markets Market Perform → Outperform
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-11 再開されました BMO Capital Markets Market Perform
2021-12-15 アップグレード Wedbush Neutral → Outperform
2021-12-07 開始されました Cowen Outperform
2021-11-09 アップグレード Citigroup Neutral → Buy
2021-08-26 開始されました Morgan Stanley Equal-Weight
2021-06-07 アップグレード H.C. Wainwright Neutral → Buy
2021-05-07 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Jefferies Buy
2021-02-26 開始されました BofA Securities Buy
2021-02-26 ダウングレード Wedbush Outperform → Neutral
2021-02-11 ダウングレード Citigroup Buy → Neutral
2021-01-27 再開されました H.C. Wainwright Neutral
2020-05-13 開始されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-09 ダウングレード BMO Capital Markets Outperform → Market Perform
2019-12-30 繰り返されました Mizuho Buy
2019-12-09 アップグレード Wells Fargo Market Perform → Outperform
2019-11-12 開始されました SunTrust Buy
2019-11-06 ダウングレード Wells Fargo Outperform → Market Perform
2019-10-01 開始されました Stifel Buy
2019-08-09 開始されました BTIG Research Buy
2019-07-22 開始されました Cantor Fitzgerald Overweight
2019-07-12 開始されました Oppenheimer Outperform
2019-06-13 開始されました Mizuho Buy
2019-06-07 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Buy
2019-05-24 再開されました Citigroup Buy
2019-03-28 開始されました SVB Leerink Outperform
2019-01-03 ダウングレード Stephens Overweight → Equal-Weight
2018-11-05 開始されました Jefferies Buy
2018-08-01 開始されました Citigroup Buy
2018-03-06 ダウングレード H.C. Wainwright Buy → Neutral
すべてを表示

Fate Therapeutics Inc (FATE) 最新ニュース

pulisher
Feb 12, 2026

Gains Recap: Can Fate Therapeutics Inc lead its sector in growthMarket Movers & Community Verified Watchlist Alerts - baoquankhu1.vn

Feb 12, 2026
pulisher
Feb 10, 2026

Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving AverageWhat's Next? - MarketBeat

Feb 10, 2026
pulisher
Feb 10, 2026

Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving Average – What’s Next? - Defense World

Feb 10, 2026
pulisher
Feb 08, 2026

Nasdaq Moves: What is the dividend yield of Fate Therapeutics IncMarket Performance Recap & Expert Approved Trade Ideas - baoquankhu1.vn

Feb 08, 2026
pulisher
Feb 04, 2026

Growth Report: What analysts say about Fate Therapeutics Inc stockJuly 2025 Catalysts & Expert-Curated Trade Recommendations - baoquankhu1.vn

Feb 04, 2026
pulisher
Feb 03, 2026

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 03, 2026
pulisher
Feb 01, 2026

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts - MarketBeat

Feb 01, 2026
pulisher
Feb 01, 2026

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts - Defense World

Feb 01, 2026
pulisher
Jan 31, 2026

Loss Report: Can Fate Therapeutics Inc ride the EV waveVolume Spike & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn

Jan 31, 2026
pulisher
Jan 30, 2026

The Truth About Fate Therapeutics Inc: Is This Biotech Underdog About To Explode Or Implode? - AD HOC NEWS

Jan 30, 2026
pulisher
Jan 23, 2026

Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets - GlobeNewswire Inc.

Jan 23, 2026
pulisher
Jan 22, 2026

Guidance Update: What analysts say about Fate Therapeutics Inc stock2025 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn

Jan 22, 2026
pulisher
Jan 20, 2026

Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving AverageHere's What Happened - MarketBeat

Jan 20, 2026
pulisher
Jan 20, 2026

Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving Average – Here’s What Happened - Defense World

Jan 20, 2026
pulisher
Jan 17, 2026

Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 6.3% over the previous year - simplywall.st

Jan 17, 2026
pulisher
Jan 16, 2026

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results - IT Business Net

Jan 16, 2026
pulisher
Jan 14, 2026

Cindy Tahl Sells 10,589 Shares of Fate Therapeutics (NASDAQ:FATE) Stock - Defense World

Jan 14, 2026
pulisher
Jan 12, 2026

Insider Selling: Fate Therapeutics (NASDAQ:FATE) Insider Sells 10,589 Shares of Stock - MarketBeat

Jan 12, 2026
pulisher
Jan 09, 2026

Does Fate Therapeutics Inc. stock trade at a discount to peers2025 Sector Review & Expert-Curated Trade Recommendations - Улправда

Jan 09, 2026
pulisher
Jan 08, 2026

Will Fate Therapeutics Inc. stock benefit from infrastructure spending2025 Market Overview & Fast Gain Stock Trading Tips - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Will Indaptus Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Technicals & Entry Point Confirmation Alerts - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Can Fate Therapeutics Inc. stock beat market expectations this quarterNew Guidance & High Accuracy Swing Entry Alerts - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Will Fate Therapeutics Inc. stock sustain high P E ratiosJuly 2025 Selloffs & AI Powered Market Entry Ideas - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Why Fate Therapeutics Inc. stock could outperform in 20252025 Bull vs Bear & Comprehensive Market Scan Insights - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Trend Review: Why Fate Therapeutics Inc stock could outperform in 2025Layoff News & Technical Buy Zone Confirmation - Bộ Nội Vụ

Jan 08, 2026
pulisher
Jan 07, 2026

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World

Jan 07, 2026
pulisher
Jan 07, 2026

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat

Jan 07, 2026
pulisher
Jan 05, 2026

Fate Therapeutics reports new employee inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Jan 05, 2026
pulisher
Jan 05, 2026

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets

Jan 05, 2026
pulisher
Jan 05, 2026

The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant

Jan 05, 2026
pulisher
Jan 01, 2026

Fate Therapeutics (NASDAQ:FATE) Shares Pass Below Two Hundred Day Moving AverageHere's Why - MarketBeat

Jan 01, 2026
pulisher
Dec 30, 2025

Who Are the Top 19 NK Cell Therapy Companies Globally? - Global Growth Insights

Dec 30, 2025
pulisher
Dec 28, 2025

ETF Watch: Can Fate Therapeutics Inc stock beat market expectations this quarterTrade Exit Summary & Growth Oriented Trading Recommendations - moha.gov.vn

Dec 28, 2025
pulisher
Dec 21, 2025

Companies Like Fate Therapeutics (NASDAQ:FATE) Could Be Quite Risky - Yahoo Finance

Dec 21, 2025
pulisher
Dec 20, 2025

Is Fate Therapeutics Inc. stock positioned for long term growth2025 EndofYear Setup & Entry Point Confirmation Signals - Улправда

Dec 20, 2025
pulisher
Dec 19, 2025

Will Fate Therapeutics Inc. stock keep outperforming rivalsEarnings Trend Report & Safe Swing Trade Setups - Улправда

Dec 19, 2025
pulisher
Dec 18, 2025

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from NASDAQ Biotechnology Index - marketscreener.com

Dec 18, 2025
pulisher
Dec 18, 2025

Why hedge funds are buying Fate Therapeutics Inc. stockJuly 2025 Spike Watch & Long-Term Growth Plans - Улправда

Dec 18, 2025
pulisher
Dec 17, 2025

Cell Therapy Technologies Market Top Players, Segments & Regional Trends by 2034 - Straits Research

Dec 17, 2025
pulisher
Dec 15, 2025

Fate Therapeutics Inc (FATE) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com

Dec 15, 2025
pulisher
Dec 09, 2025

Healthy Upside Potential: Fate Therapeutics Inc (FATE) - setenews.com

Dec 09, 2025
pulisher
Dec 09, 2025

Fate Therapeutics Inc Stock Analysis and ForecastMarket Profile Overview & Fast Profit Portfolio Plans - earlytimes.in

Dec 09, 2025
pulisher
Dec 08, 2025

Fate Therapeutics reports positive lupus treatment data at ASH meeting - Investing.com

Dec 08, 2025
pulisher
Dec 08, 2025

Fate Therapeutics reports positive lupus treatment data at ASH meeting By Investing.com - Investing.com Canada

Dec 08, 2025
pulisher
Dec 08, 2025

Fate Therapeutics Reports Positive Clinical Updates for FT819 in Systemic Lupus Erythematosus and Introduces Next-Generation CAR T-Cell Programs at ASH Annual Meeting - Quiver Quantitative

Dec 08, 2025
pulisher
Dec 08, 2025

Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs - The Manila Times

Dec 08, 2025

Fate Therapeutics Inc (FATE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$44.80
price up icon 1.24%
$26.75
price down icon 0.19%
$100.75
price up icon 1.93%
$105.76
price down icon 3.31%
$146.17
price down icon 1.52%
biotechnology ONC
$346.42
price down icon 1.38%
大文字化:     |  ボリューム (24 時間):